NICE Backs Xgeva for Oncology But Excludes Prostate Cancer Indication
This article was originally published in The Pink Sheet Daily
Executive Summary
A significant discount from Amgen has left NICE more than happy to pass Xgeva, but it still found economic grounds to reject the company’s application for a prostate cancer indication.